bile duct cancer
Jazz Pharma Seeking Approval for Zanidatamab in HER2-Positive Biliary Tract Cancer
The application was based on Phase IIb trial results showing a 41 percent response rate on zanidatamab in this setting.
The study didn't meet its prespecified endpoint but suggests potential activity in HER2-amplified urothelial cancer and cholangiocarcinoma.
In Brief This Week: A2 Biotherapeutics, Ellipses Pharma, Quanterix, Verismo Therapeutics
News items for the week of March 4, 2024.
FDA Grants Priority Review to Enhertu for Metastatic HER2-Positive Solid Tumors
Daiichi Sankyo and AstraZeneca filed a supplemental biologics application for Enhertu based on clinical benefit shown in the DESTINY-PanTumor02 trial.
Haystack Oncology, TriSalus Partner on Liver, Pancreatic Cancer Clinical Studies
The firms will apply Haystack's minimal residual disease platform to TriSalus' ongoing clinical trials in liver, bile duct, and pancreatic cancer.
Jun 3, 2023